Antibody therapeutics targeting ion channels: are we there yet?

Acta Pharmacol Sin. 2013 Feb;34(2):199-204. doi: 10.1038/aps.2012.202.

Abstract

The combination of technological advances, genomic sequences and market success is catalyzing rapid development of antibody-based therapeutics. Cell surface receptors and ion channel proteins are well known drug targets, but the latter has seen less success. The availability of crystal structures, better understanding of gating biophysics and validation of physiological roles now form an excellent foundation to pursue antibody-based therapeutics targeting ion channels to treat a variety of diseases.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies / immunology
  • Antibodies / therapeutic use*
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / immunology
  • Autoimmune Diseases / metabolism
  • Drug Discovery / methods*
  • Humans
  • Ion Channels / immunology*
  • Ion Channels / metabolism
  • Molecular Targeted Therapy / methods*

Substances

  • Antibodies
  • Ion Channels